SD Biosensor Inc Total Assets
SD Biosensor Inc total assets. Based on the latest financial reports, SD Biosensor Inc (137310) holds total assets worth ₩2.90 Trillion KRW (≈ $1.97 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 137310 market cap for the company's overall valuation and market capitalisation.
Total Assets of SD Biosensor Inc (2019–2025)
Total assets of SD Biosensor Inc from 2019 to 2025. This chart illustrates how SD Biosensor Inc's total assets have evolved over time, based on quarterly financial data. See latest SD Biosensor Inc stock price today for real-time trading data and today's change.
SD Biosensor Inc - Asset Composition Analysis
SD Biosensor Inc Total Assets Breakdown (December 2025)
SD Biosensor Inc total assets breakdown as of December 2025. SD Biosensor Inc's total assets of ₩2.90 Trillion consist of 38.0% current assets and 62.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 11.3% |
| Accounts Receivable | ₩138.07 Billion | 4.3% |
| Inventory | ₩222.11 Billion | 6.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩472.39 Billion | 14.6% |
| Goodwill | ₩784.97 Billion | 24.2% |
Asset Composition Trend (2019–2025)
This chart illustrates how SD Biosensor Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 137310 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SD Biosensor Inc's current assets represent 38.0% of total assets in 2025, a decrease from 63.4% in 2019.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, the same as 11.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 2.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 24.2% of total assets.
SD Biosensor Inc Competitors by Total Assets
Key competitors of SD Biosensor Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
T&L Co. Ltd
KQ:340570
|
Korea | ₩253.22 Billion |
|
Paxman AB
ST:PAX
|
Sweden | Skr487.65 Million |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
ORTOMA AB B
F:82Y
|
Germany | €161.34 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
SD Biosensor Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.51 | 7.52 | 4.08 |
| Quick Ratio | 4.75 | 6.04 | 3.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩773.01 Billion | ₩1.05 Trillion | ₩1.84 Trillion |
SD Biosensor Inc - Advanced Valuation Insights
This section examines the relationship between SD Biosensor Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.30 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -16.6% |
| Total Assets | ₩3.24 Trillion |
| Market Capitalization | $522.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values SD Biosensor Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SD Biosensor Inc's assets decreased by 16.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SD Biosensor Inc (2019–2025)
The table below shows the annual total assets of SD Biosensor Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩3.24 Trillion ≈ $2.20 Billion |
-16.61% |
| 2024-12-31 | ₩3.89 Trillion ≈ $2.64 Billion |
+2.63% |
| 2023-12-31 | ₩3.79 Trillion ≈ $2.57 Billion |
+16.15% |
| 2022-12-31 | ₩3.26 Trillion ≈ $2.21 Billion |
+8.55% |
| 2021-12-31 | ₩3.01 Trillion ≈ $2.04 Billion |
+105.60% |
| 2020-12-31 | ₩1.46 Trillion ≈ $990.54 Million |
+761.22% |
| 2019-12-31 | ₩169.72 Billion ≈ $115.02 Million |
-- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more